Effect of stent coating alone on in-vitro vascular smooth muscle cell proliferation and adoptosis  by unknown
Progression of early carotid atherosclerosis is only temporarily reduced
after antibiotic treatment of Chlamydia pneumoniae seropositivity
Sander B, Winbeck K, Klingelhofer J, et al. Circulation 2004;109:1010-5.
Conclusion: Antibiotic therapy has only a limited effect on atheroscle-
rotic progression in patients with seropositive Chlamydia pneumoniae (Cp)
infection.
Summary: Seropositivity for Cp is associated with atherosclerosis.
Effects of antibiotic therapy on future cardiovascular end points are un-
known in patients with Cp infection. The authors studied the effects of a
30-day treatment course with roxithromycin on intima-media thickness
(IMT) progression in the common carotid arteries of 272 patients with
ischemic stroke. Patients were analyzed for Cp-positive and Cp-negative
status, and the drug was administered in a prospective double-blind random-
ized protocol with a follow-up of 4 years. Forty-six percent of patients (n 
125) were seropositive for Cp infection. During 3 years prior to antibiotic
therapy, and after adjusting for other atherosclerotic risk factors, CP-positive
patients had increased IMT progression (0.12 [0.11-0.14] vs 0.07 [0.05-
0.09] mm/y; P .005). Roxithromycin was administered to 62 Cp-positive
patients. These patients had reduced IMT progression during the first 2
years compared with Cp-positive patients not treated with roxithromycin
(0.07 [0.045-0.095] vs 0.11 [0.088-0.132] mm/y; P  .01). However,
during the third and fourth years of the study, IMP progression again
increased in antibiotic-treated patients to values similar to those before
treatment. There were no differences between groups with regard to fol-
low-up cardiovascular events.
Comment: Epidemiologic, histopathologic, and in vitro animal mod-
els suggest Cp as an agent that causes or facilitates the development of
atherosclerosis. Several large antibiotic studies have, however, failed to
detect clinical benefit of antibiotic therapy in the prevention of clinical events
secondary to atherosclerosis (Circulation 2003;107:1253-9 and Circulation
2002;106:1219-23). The authors’ data suggest long treatment periods may
be required to demonstrate benefit of antibiotic therapy in reduction of
clinical events associated with atherosclerosis. Trials assessing therapy for 2
years are currently in progress (Circulation 2003;107:1228-30).
Outcome of conservative therapy of patients with severe intermittent
claudication
Amighi J, Sabeti F, Schlager O, et al. Eur J Vasc Endovasc Surg 2004;27:
254-8.
Conclusions: Risk factor modification and recommendations for phys-
ical training result in substantial clinical improvement in patients with severe
intermittent claudication.
Summary: In this retrospective cohort study the authors evaluated the
effects of risk factor modification and recommendations for physical training
(at least 60 minutes per day of walking) on intermittent claudication.
Supervised physical training was not performed as part of this study. There
were 181 patients with a median age of 71 years (interquartile range, 60-76
years). Ninety-two patients were male. All patients had Fontaine stage 2B
claudication of at least 1 lower limb. Patients were evaluated for Fontaine
stage, walking distance, and ankle brachial index (ABI) at baseline and after
a median of 9 months of follow-up.
Improvement of at least 1 Fontaine stage occurred in 38 patients (21%)
with an increased walking distance from baseline (median 100 meters;
interquartile range, 50-150 meters), to a median walking distance at fol-
low-up of 650 meters (interquartile range, 300 meters to unlimited; P 
.001). There was no associated change in ABI, with a median ABI at baseline
of 0.57 and at follow-up 0.54. One hundred and thirty-eight patients (76%)
remained clinically and hemodynamically stable. A worsening of Fontaine
stage without amputation was recorded in 5 patients (3%). A reduced
probability of clinical improvement was associated with female gender
(hazard ratio [HR] 0.51; P  .052), diabetes (HR 0.35; P  .020) and
baseline ABI below 0.44 (HR 0.31; P  .019).
Comment: The article reinforces the wisdom of conservative manage-
ment of even those patients with severe symptoms of intermittent claudica-
tion. Based on the authors’ analysis, patients who are female, have diabetes,
and a baseline ABI 0.4 can be advised that they are less likely to improve
than other patients with similar symptoms, but also are very unlikely to
deteriorate in short-term follow-up.
Effect of stent coating alone on in vitro vascular smooth muscle cell
proliferation and apoptosis
Curcil A, Torella D, Cuda G, et al. Am J Physiol Heart Circ Physiol
2004;286:H902-8.
Conclusion: Synthetic polymers employed as drug delivery systems for
drug-coded stents are not inert platforms for drug delivery but have biologic
affects on smooth muscle cell growth and proliferation.
Summary: Synthetic polymers are used as coatings on stents to deliver
drugs locally to inhibit restenosis. The authors sought to evaluate the effect
of methacrylate (MA) compounds on in vitro vascular smooth muscle cell
(VSMC) proliferation. Stainless steel stents were coded with MA at doses of
0.3, 1.5, and 3 mL. Bare metal stents were used as controls. VSMCs were
cultured. MA-coded stents or bare metal stents were added to the cultures.
VSMC proliferation was assessed by bromodeoxyuribine (BRDU) incorpo-
ration. Apoptosis was analyzed using 3 different standardized techniques.
With both high and low concentrations, MA-coated stents induced a
significant decrease of VSMC BRDU incorporation. VSMCs incubated with
MA-coated stents showed significant increases in the numbers of apoptotic
cells. The MA-coated stent induced VSMC proliferative arrest in a dose-
dependent manner.
Comment: Huge efforts are underway to determine the best drug for
a drug-eluting stent. The current study indicates that the polymers used to
deliver the drugs may also have biologic activity. Biocompatibility between
delivery polymers and drugs must therefore be considered in the design of
drug-eluting stents. Overall success of drug-eluting stents might be depen-
dent not only on the drug but also on the polymer component of the delivery
system.
Risk of pulmonary embolism after negative MDCT pulmonary angiog-
raphy findings
Kavanag HEC, O’Hare A, Hargaden G, Murry JG. Am J Radiol 2004;182:
499-504.
Conclusion: At a mean of 9 months of follow-up, there is minimal risk
of pulmonary embolism (PE) after negative multidetector computed to-
mography (MDCT) pulmonary angiogram.
Summary: This was a prospective study of 102 consecutive patients
with suspected PE who underwent MDCT pulmonary angiography. Each
scan was reviewed by 2 observers. Findings were recorded by consensus.
Observers were asked to note whether PE or other disease was present.
No PE was seen in 85 patients who were then followed for a mean of 9
months (range, 4-13 months) for evidence of subsequent PE. There were 52
men and 33 women (age range, 20-94 years; mean, 60 years) who were
entered into the follow-up protocol. Follow-up was performed using clinical
interview by telephone, interview with primary care or referring clinicians,
chart review, review of autopsy reports, or review of death certificates. A
diagnosis of subsequent PE was based on findings of subsequent ventilation
perfusion scanning, pulmonary angiography, CT pulmonary angiography,
or autopsy.
In follow-up, only 1 patient had a diagnosis of PE. This diagnosis was
made in 3 weeks by high-probability ventilation perfusion scan and sub-
sequent CT pulmonary angiography. MDCT pulmonary angiography
showed additional potentially significant abnormalities in 76% of patients.
These findings were not suspected on plain chest x-rays in 47%.
Comment: CT pulmonary angiography has already replaced ventila-
tion perfusion scanning as the noninvasive test of choice for diagnosis of PE.
It has, in most cases, also replaced catheter-based pulmonary angiography.
Ventilation perfusion scanning and catheter-based pulmonary angiography
for diagnosis of PE are rapidly following the path of the whaler and buffalo
hunter. They will not be needed and few will miss them.
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